Prostate cancer immunotherapy

Kenneth F. May; James L. Gulley; Charles G. Drake; Glenn Dranoff; Philip W. Kantoff

doi:10.1158/1078-0432.CCR-10-3402

Prostate cancer immunotherapy

Kenneth F. May, James L. Gulley, Charles G. Drake, Glenn Dranoff, Philip W. Kantoff

School of Medicine

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

The interaction between the immune system and prostate cancer has been an area of research interest for several decades. The recent U.S. Food and Drug Administration approval of 2 first-in-class proof-of-concept immunotherapies (sipuleucel-T and ipilimumab) has stimulated broader interest in manipulating immunity to fight cancer. In the context of prostate cancer, the immunotherapy strategies that have garnered the most interest are the therapeutic vaccination strategies, exemplified by sipuleucel-T and PROSTVAC-VF, and immune checkpoint blockade of CTLA-4 and PD-1. Improved understanding of the immune responses generated by these strategies and development of predictive biomarkers for patient selection will guide rational combinations of these treatments and provide building blocks for future immunotherapies.

Original language	English (US)
Pages (from-to)	5233-5238
Number of pages	6
Journal	Clinical Cancer Research
Volume	17
Issue number	16
DOIs	https://doi.org/10.1158/1078-0432.CCR-10-3402
State	Published - Aug 15 2011

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1158/1078-0432.CCR-10-3402

Cite this

@article{b3abac348df346bba8fa3fd10aa5ea13,

title = "Prostate cancer immunotherapy",

abstract = "The interaction between the immune system and prostate cancer has been an area of research interest for several decades. The recent U.S. Food and Drug Administration approval of 2 first-in-class proof-of-concept immunotherapies (sipuleucel-T and ipilimumab) has stimulated broader interest in manipulating immunity to fight cancer. In the context of prostate cancer, the immunotherapy strategies that have garnered the most interest are the therapeutic vaccination strategies, exemplified by sipuleucel-T and PROSTVAC-VF, and immune checkpoint blockade of CTLA-4 and PD-1. Improved understanding of the immune responses generated by these strategies and development of predictive biomarkers for patient selection will guide rational combinations of these treatments and provide building blocks for future immunotherapies.",

author = "May, {Kenneth F.} and Gulley, {James L.} and Drake, {Charles G.} and Glenn Dranoff and Kantoff, {Philip W.}",

year = "2011",

month = aug,

day = "15",

doi = "10.1158/1078-0432.CCR-10-3402",

language = "English (US)",

volume = "17",

pages = "5233--5238",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "16",

}

TY - JOUR

T1 - Prostate cancer immunotherapy

AU - May, Kenneth F.

AU - Gulley, James L.

AU - Drake, Charles G.

AU - Dranoff, Glenn

AU - Kantoff, Philip W.

PY - 2011/8/15

Y1 - 2011/8/15

N2 - The interaction between the immune system and prostate cancer has been an area of research interest for several decades. The recent U.S. Food and Drug Administration approval of 2 first-in-class proof-of-concept immunotherapies (sipuleucel-T and ipilimumab) has stimulated broader interest in manipulating immunity to fight cancer. In the context of prostate cancer, the immunotherapy strategies that have garnered the most interest are the therapeutic vaccination strategies, exemplified by sipuleucel-T and PROSTVAC-VF, and immune checkpoint blockade of CTLA-4 and PD-1. Improved understanding of the immune responses generated by these strategies and development of predictive biomarkers for patient selection will guide rational combinations of these treatments and provide building blocks for future immunotherapies.

AB - The interaction between the immune system and prostate cancer has been an area of research interest for several decades. The recent U.S. Food and Drug Administration approval of 2 first-in-class proof-of-concept immunotherapies (sipuleucel-T and ipilimumab) has stimulated broader interest in manipulating immunity to fight cancer. In the context of prostate cancer, the immunotherapy strategies that have garnered the most interest are the therapeutic vaccination strategies, exemplified by sipuleucel-T and PROSTVAC-VF, and immune checkpoint blockade of CTLA-4 and PD-1. Improved understanding of the immune responses generated by these strategies and development of predictive biomarkers for patient selection will guide rational combinations of these treatments and provide building blocks for future immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=80051682043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051682043&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-3402

DO - 10.1158/1078-0432.CCR-10-3402

M3 - Article

C2 - 21700764

AN - SCOPUS:80051682043

SN - 1078-0432

VL - 17

SP - 5233

EP - 5238

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 16

ER -

Prostate cancer immunotherapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this